Overview
- Health authorities report more than 10,000 confirmed Ebola cases and roughly 5,000 deaths in the Democratic Republic of Congo, and experts say the true number of infections may be two to three times higher than official counts.
- A German laboratory study found that people vaccinated with Ervebo generate T‑cell responses that can recognize the Bundibugyo virus, but those lab results do not prove the vaccine prevents illness or death from this variant.
- The Tumaini adaptive vaccine trial began on 23 October in Bunia using ring vaccination with tens of thousands of Ervebo doses to measure clinical effectiveness and to add Bundibugyo‑specific candidates from Oxford and Moderna once safety checks are complete.
- Response and research are being hampered by armed conflict, attacks on health workers and facilities, weak transport and diagnostic capacity, incomplete contact tracing, and concerns about vaccine supply and access.
- Targeted Bundibugyo vaccines remain in early human testing and developers and experts say broad public availability is unlikely before mid‑2027, while the outbreak continues to strain local health services and has produced exported cases in several countries.